Julia Calvo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Calvo has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Ana González-Cordón
HIV Unit, Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
9 shared publications - Alberto Foncillas
HIV Unit, Infectious Diseases Department, Hospital Clínic de Barcelona Barcelona Spain
8 shared publications - Berta Torres
HIV Unit, Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
8 shared publications - Elisa de Lazzari
HIV Unit, Infectious Diseases Department, Hospital Clínic de Barcelona Barcelona Spain
8 shared publications - Maria Martínez-Rebollar
HIV Unit, Infectious Diseases Department, Hospital Clínic de Barcelona Barcelona Spain
8 shared publications - Esteban Martinez
Infectious Diseases Unit Hospital Clínic Barcelona Spain
7 shared publications
Latest Publications
- 22 October 2026
- Published by Wiley in HIV Medicine
Sex‐ and migration‐related differences in viral suppression and life expectancy among people with HIV : The PISCIS cohort, 1998–2023
Background: Despite advances in antiretroviral therapy (ART), inequalities in HIV outcomes persist by sex and migration status. Few studies have examined how these factors jointly relate to treatment outcomes across successive ART eras. Aim: To examine differences in time to first viral suppression and life expectancy according to sex and migration status, and how these differences changed across successive ART eras. Methods: We conducted a population‐based retrospective cohort study using the PISCIS cohort in Catalonia and the Balearic Islands, Spain. Participants aged ≥16 years diagnosed with HIV between 1998 and 2023, with a recorded ART initiation date and at least one viral load measurement within 12 months after ART initiation, were included. Time to first viral suppression (p < 0.001): Migrant women had a lower adjusted hazard of viral suppression than migrant MSM (aHR 0.77, 95% CI 0.67–0.89), while a particularly low hazard was observed among migrant heterosexual men (aHR 0.60, 95% CI 0.51–0.69). Life expectancy at age 20 increased by approximately 12 years across all groups over the study period, with differences between groups narrowing over time. Conclusion: Viral suppression and life expectancy improved substantially across all sex‐migration groups over 26 years. However, differences in time to viral suppression persisted in the most recent ART era, including slower suppression among migrant women compared with migrant men. Further disaggregation of sexually acquired HIV revealed additional heterogeneity, particularly between migrant MSM and heterosexual men. These findings highlight the importance of considering the intersection of sex, migration status and HIV acquisition group to better identify population‐specific inequalities in HIV care.
- 22 October 2026
- Published by Wiley in HIV Medicine
Sex‐ and migration‐related differences in viral suppression and life expectancy among people with HIV : The PISCIS cohort, 1998–2023
Background: Despite advances in antiretroviral therapy (ART), inequalities in HIV outcomes persist by sex and migration status. Few studies have examined how these factors jointly relate to treatment outcomes across successive ART eras. Aim: To examine differences in time to first viral suppression and life expectancy according to sex and migration status, and how these differences changed across successive ART eras. Methods: We conducted a population‐based retrospective cohort study using the PISCIS cohort in Catalonia and the Balearic Islands, Spain. Participants aged ≥16 years diagnosed with HIV between 1998 and 2023, with a recorded ART initiation date and at least one viral load measurement within 12 months after ART initiation, were included. Time to first viral suppression (p < 0.001): Migrant women had a lower adjusted hazard of viral suppression than migrant MSM (aHR 0.77, 95% CI 0.67–0.89), while a particularly low hazard was observed among migrant heterosexual men (aHR 0.60, 95% CI 0.51–0.69). Life expectancy at age 20 increased by approximately 12 years across all groups over the study period, with differences between groups narrowing over time. Conclusion: Viral suppression and life expectancy improved substantially across all sex‐migration groups over 26 years. However, differences in time to viral suppression persisted in the most recent ART era, including slower suppression among migrant women compared with migrant men. Further disaggregation of sexually acquired HIV revealed additional heterogeneity, particularly between migrant MSM and heterosexual men. These findings highlight the importance of considering the intersection of sex, migration status and HIV acquisition group to better identify population‐specific inequalities in HIV care.
- Open Access
- 11 September 2026
- Published by Wiley in HIV Medicine
Venezuelan migrants living with HIV in Barcelona : Migration patterns and baseline immunovirological characteristics in a retrospective cohort study
Objectives: To describe the sociodemographic characteristics, migration patterns and immunovirological outcomes of Venezuelan migrants living with HIV (PLWH) in Barcelona, Spain, and to compare them with other Latin American (LA) migrant PLWH. Methods: We conducted a retrospective observational cohort study including LA migrant PLWH who attended their first consultation at the HIV Unit of Hospital Clínic de Barcelona between 2000 and 2023. Venezuelan PLWH were compared with other LA migrant PLWH regarding demographics, HIV diagnosis timing, CD4 cell count, viral load, late HIV diagnosis (LHD) and advanced HIV disease (AHD). Results: A total of 493 Venezuelan PLWH were included, representing 16% of LA migrant PLWH in the cohort. Venezuelan PLWH were predominantly men (97%; n = 478). Most first consultations occurred after 2014 (81%; n = 399), peaking in 2018. Half were diagnosed with HIV after arrival in Spain (50%; 224/451), and 73% (328/451) had lived in Spain for less than 3 years. Among ART‐naïve individuals, LHD was 38% in 2000–2008 and 53% in 2015–2023, while baseline CD4 counts progressively declined. Immunological outcomes were similar between Venezuelan and other LA migrants, including LHD (50%; n = 98 vs. 51%; n = 622) and AHD (24%; n = 48 vs. 25%; n = 301). However, ART‐experienced Venezuelan PLWH showed lower virological suppression rates (67%; n = 191 vs. 72%; n = 1013; p = 0.068). Conclusion: Venezuelan PLWH in this Barcelona cohort represent a rapidly growing migrant population shaped by humanitarian displacement and disruption of HIV care. The high proportion of LHD and lower virological suppression among ART‐experienced individuals is compatible with continuity‐of‐care disruptions before migration but do not establish causality.
- 11 September 2026
- Published by Wiley in HIV Medicine
Open AccessVenezuelan migrants living with HIV in Barcelona : Migration patterns and baseline immunovirological characteristics in a retrospective cohort study
Objectives: To describe the sociodemographic characteristics, migration patterns and immunovirological outcomes of Venezuelan migrants living with HIV (PLWH) in Barcelona, Spain, and to compare them with other Latin American (LA) migrant PLWH. Methods: We conducted a retrospective observational cohort study including LA migrant PLWH who attended their first consultation at the HIV Unit of Hospital Clínic de Barcelona between 2000 and 2023. Venezuelan PLWH were compared with other LA migrant PLWH regarding demographics, HIV diagnosis timing, CD4 cell count, viral load, late HIV diagnosis (LHD) and advanced HIV disease (AHD). Results: A total of 493 Venezuelan PLWH were included, representing 16% of LA migrant PLWH in the cohort. Venezuelan PLWH were predominantly men (97%; n = 478). Most first consultations occurred after 2014 (81%; n = 399), peaking in 2018. Half were diagnosed with HIV after arrival in Spain (50%; 224/451), and 73% (328/451) had lived in Spain for less than 3 years. Among ART‐naïve individuals, LHD was 38% in 2000–2008 and 53% in 2015–2023, while baseline CD4 counts progressively declined. Immunological outcomes were similar between Venezuelan and other LA migrants, including LHD (50%; n = 98 vs. 51%; n = 622) and AHD (24%; n = 48 vs. 25%; n = 301). However, ART‐experienced Venezuelan PLWH showed lower virological suppression rates (67%; n = 191 vs. 72%; n = 1013; p = 0.068). Conclusion: Venezuelan PLWH in this Barcelona cohort represent a rapidly growing migrant population shaped by humanitarian displacement and disruption of HIV care. The high proportion of LHD and lower virological suppression among ART‐experienced individuals is compatible with continuity‐of‐care disruptions before migration but do not establish causality.
- 1 September 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (10)
Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study
Objectives: The objective of this study is to evaluate the efficacy, resistance profile, pharmacokinetics (PK) and safety of switching from etravirine to doravirine in virologically suppressed, treatment-experienced individuals with prior non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations (NNRTI-RAMs). Methods: DorSwitch is a prospective pilot study including 13 adults with sustained virological suppression and documented historical NNRTI-RAMs. Etravirine was replaced by doravirine while maintaining the remaining antiretroviral backbone. Drug-specific resistance penalty scores were generated using the Stanford HIV Drug Resistance Database (HIVdb) algorithm. PK analyses were performed in participants receiving darunavir/cobicistat plus doravirine. Virological, immunological, metabolic and safety outcomes were assessed over 48 weeks. Results: Twelve participants completed 48 weeks of follow-up; one discontinued at Week 4 for personal reasons while virologically suppressed. All participants evaluable at Weeks 24 and 48 maintained HIV-1 RNA < 50 copies/mL, and no virological failures occurred. The median number of NNRTI-RAMs per individual was 2 (IQR 1–3). Doravirine showed lower or equal Stanford HIVdb penalty score (HIVdb-PS) than etravirine in 11/13 participants. In two cases, higher doravirine PS were driven by Y318F and G190E mutations detected in peripheral blood mononuclear cell HIV-1 DNA; both individuals remained virologically suppressed through Week 48. In seven participants receiving darunavir/cobicistat plus doravirine, trough concentrations (Cmin) were consistent with expected exposure concentrations. Total cholesterol and LDL cholesterol decreased significantly over follow-up, while body weight showed a modest, non-significant reduction. No doravirine-related serious adverse events were observed. Conclusions: In this small, highly selected pilot cohort, switching from etravirine to doravirine as part of an otherwise suppressive regimen was associated with maintenance of virological suppression through Week 48 and a more favourable predicted NNRTI resistance profile in most participants. The favourable resistance profile, safety, metabolic effects and PK findings consistent with expected exposure—particularly in combination with darunavir/cobicistat— support further evaluation of doravirine as a switch option in carefully selected individuals with prior NNRTI failure.
- 1 September 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (10)
Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study
Objectives: The objective of this study is to evaluate the efficacy, resistance profile, pharmacokinetics (PK) and safety of switching from etravirine to doravirine in virologically suppressed, treatment-experienced individuals with prior non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations (NNRTI-RAMs). Methods: DorSwitch is a prospective pilot study including 13 adults with sustained virological suppression and documented historical NNRTI-RAMs. Etravirine was replaced by doravirine while maintaining the remaining antiretroviral backbone. Drug-specific resistance penalty scores were generated using the Stanford HIV Drug Resistance Database (HIVdb) algorithm. PK analyses were performed in participants receiving darunavir/cobicistat plus doravirine. Virological, immunological, metabolic and safety outcomes were assessed over 48 weeks. Results: Twelve participants completed 48 weeks of follow-up; one discontinued at Week 4 for personal reasons while virologically suppressed. All participants evaluable at Weeks 24 and 48 maintained HIV-1 RNA < 50 copies/mL, and no virological failures occurred. The median number of NNRTI-RAMs per individual was 2 (IQR 1–3). Doravirine showed lower or equal Stanford HIVdb penalty score (HIVdb-PS) than etravirine in 11/13 participants. In two cases, higher doravirine PS were driven by Y318F and G190E mutations detected in peripheral blood mononuclear cell HIV-1 DNA; both individuals remained virologically suppressed through Week 48. In seven participants receiving darunavir/cobicistat plus doravirine, trough concentrations (Cmin) were consistent with expected exposure concentrations. Total cholesterol and LDL cholesterol decreased significantly over follow-up, while body weight showed a modest, non-significant reduction. No doravirine-related serious adverse events were observed. Conclusions: In this small, highly selected pilot cohort, switching from etravirine to doravirine as part of an otherwise suppressive regimen was associated with maintenance of virological suppression through Week 48 and a more favourable predicted NNRTI resistance profile in most participants. The favourable resistance profile, safety, metabolic effects and PK findings consistent with expected exposure—particularly in combination with darunavir/cobicistat— support further evaluation of doravirine as a switch option in carefully selected individuals with prior NNRTI failure.
- Open Access
- 19 August 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Annual vs Semi-Annual Follow-up in Low-Complexity, Virologically Suppressed People With HIV: A Randomized Interventional Trial
Background: Increasing heterogeneity among people with HIV requires evaluation of new follow-up strategies tailored to clinical/social complexity. Methods: Prospective, single-center, randomized, noninferiority trial comparing semi-annual standard of care (SoC) with annual follow-upover 24 months in virologically suppressed people with HIV with low-complexity profile according to the GeSIDA HIV Patient Stratification System. The primary endpoint was noninferiority (prespecified lower margin: −4%) in virological control (viral load <50 copies/mL; FDA snapshot). Secondary outcomes included adherence, quality of life, satisfaction, and healthcare costs. Results: Of 394 eligible candidates, 71 declined participation (48% preferred SoC) and 321 were randomized (162 SoC, 159 Annual). Participants were predominantly male (89%), men who have sex with men (78%), Spanish (63%), with a median age of 45 years and 13 years of HIV follow-up, without baseline differences between groups. Overall, 283 (88%) completed the study; 25 switched to long-acting therapy and 10 were lost or transferred. Virological control was similar in SoC and annual arms: 86.42% vs 86.79% (intention to treat) and 98.29% vs 97.87% (per protocol), although noninferiority was not statistically demonstrated. The proportion of highly satisfied participants increased significantly from baseline to 24 months in the annual arm (P = .001). Reductions in HIV-related direct costs (−25.3%; P < .001) were greater in the Annual group. Conclusions: Among people with HIV and low complexity, annual follow-up achieved virological outcomes clinically comparable to semi-annual care, despite not meeting the formal noninferiority threshold. Annual follow-up was associated with a significant increment in patient satisfaction and lower HIV-related direct costs.
- 19 August 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessAnnual vs Semi-Annual Follow-up in Low-Complexity, Virologically Suppressed People With HIV: A Randomized Interventional Trial
Background: Increasing heterogeneity among people with HIV requires evaluation of new follow-up strategies tailored to clinical/social complexity. Methods: Prospective, single-center, randomized, noninferiority trial comparing semi-annual standard of care (SoC) with annual follow-upover 24 months in virologically suppressed people with HIV with low-complexity profile according to the GeSIDA HIV Patient Stratification System. The primary endpoint was noninferiority (prespecified lower margin: −4%) in virological control (viral load <50 copies/mL; FDA snapshot). Secondary outcomes included adherence, quality of life, satisfaction, and healthcare costs. Results: Of 394 eligible candidates, 71 declined participation (48% preferred SoC) and 321 were randomized (162 SoC, 159 Annual). Participants were predominantly male (89%), men who have sex with men (78%), Spanish (63%), with a median age of 45 years and 13 years of HIV follow-up, without baseline differences between groups. Overall, 283 (88%) completed the study; 25 switched to long-acting therapy and 10 were lost or transferred. Virological control was similar in SoC and annual arms: 86.42% vs 86.79% (intention to treat) and 98.29% vs 97.87% (per protocol), although noninferiority was not statistically demonstrated. The proportion of highly satisfied participants increased significantly from baseline to 24 months in the annual arm (P = .001). Reductions in HIV-related direct costs (−25.3%; P < .001) were greater in the Annual group. Conclusions: Among people with HIV and low complexity, annual follow-up achieved virological outcomes clinically comparable to semi-annual care, despite not meeting the formal noninferiority threshold. Annual follow-up was associated with a significant increment in patient satisfaction and lower HIV-related direct costs.
- Open Access
- 18 August 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Long‐acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real‐world case series
Background: Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce. Methods: We conducted an observational, prospective, single‐centre cohort study including all people with HIV (PVIH) who initiated LA‐CAB + RPV at Hospital Clínic of Barcelona since February 2023 until April 2026. Patients receiving chronic anticoagulation during the follow‐up were identified and assessed for safety and virological outcomes. Results: Among 964 PVIH who started LA‐CAB + RPV in our cohort, three were identified who received concomitantly chronic anticoagulation (direct oral anticoagulants or low‐molecular‐weight heparin). They received injections using standard deep intramuscular technique with post‐injection compression. No clinically relevant injection‐site hematomas or haemorrhagic complications were observed. Viral suppression was maintained in all cases. Conclusions: This real‐world case series suggest that chronic anticoagulant therapy alone should not automatically preclude the use of LA‐CAB + RPV. With careful patient selection and appropriate injection techniques, LA‐CAB + RPV may represent a safe and effective treatment option for selected people with HIV receiving anticoagulation.
- 18 August 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Open AccessLong‐acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real‐world case series
Background: Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce. Methods: We conducted an observational, prospective, single‐centre cohort study including all people with HIV (PVIH) who initiated LA‐CAB + RPV at Hospital Clínic of Barcelona since February 2023 until April 2026. Patients receiving chronic anticoagulation during the follow‐up were identified and assessed for safety and virological outcomes. Results: Among 964 PVIH who started LA‐CAB + RPV in our cohort, three were identified who received concomitantly chronic anticoagulation (direct oral anticoagulants or low‐molecular‐weight heparin). They received injections using standard deep intramuscular technique with post‐injection compression. No clinically relevant injection‐site hematomas or haemorrhagic complications were observed. Viral suppression was maintained in all cases. Conclusions: This real‐world case series suggest that chronic anticoagulant therapy alone should not automatically preclude the use of LA‐CAB + RPV. With careful patient selection and appropriate injection techniques, LA‐CAB + RPV may represent a safe and effective treatment option for selected people with HIV receiving anticoagulation.
- Open Access
- 9 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1752
Community-Associated Methicillin-Resistant Staphylococcus aureus Among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV Who Engage in Chemsex in Barcelona, Spain: Epidemiological Patterns and Implications for Infection Control
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections are increasingly reported among gay, bisexual, and other men who have sex with men (GBMSM) engaging in chemsex, yet data remain limited. This ambispective cohort study conducted at Hospital Clínic of Barcelona (2018–2024) aimed to characterize CA-MRSA infections among GBMSM living with HIV. Methods: Epidemiological, behavioral, and clinical data were collected from medical records and standardized questionnaires. MRSA isolates from clinically indicated samples were identified by mass spectrometry and underwent antimicrobial susceptibility testing. Results: Among 446 participants, 62 (14%) were diagnosed with CA-MRSA, accounting for 109 infection episodes over a median follow-up of 3.21 years (IQR 1.39–5.05). All episodes involved skin and soft-tissue infections; 17% required hospitalization, 35% surgery, and 51% received non-active empirical antibiotics. Recurrent infections occurred in 32% of participants, and detectable HIV viral load was present in 28% of episodes. High levels of polydrug use were reported. Resistance to clindamycin (33%), cotrimoxazole (23%), and mupirocin (96%) was observed. Decolonization was attempted in 65% of participants. Conclusions: CA-MRSA infections were frequent, with substantial recurrence and antimicrobial resistance. These findings highlight challenges for infection control and antimicrobial stewardship and support further evaluation of preventive and decolonization strategies in this population.
- 9 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1752
Open AccessCommunity-Associated Methicillin-Resistant Staphylococcus aureus Among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV Who Engage in Chemsex in Barcelona, Spain: Epidemiological Patterns and Implications for Infection Control
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections are increasingly reported among gay, bisexual, and other men who have sex with men (GBMSM) engaging in chemsex, yet data remain limited. This ambispective cohort study conducted at Hospital Clínic of Barcelona (2018–2024) aimed to characterize CA-MRSA infections among GBMSM living with HIV. Methods: Epidemiological, behavioral, and clinical data were collected from medical records and standardized questionnaires. MRSA isolates from clinically indicated samples were identified by mass spectrometry and underwent antimicrobial susceptibility testing. Results: Among 446 participants, 62 (14%) were diagnosed with CA-MRSA, accounting for 109 infection episodes over a median follow-up of 3.21 years (IQR 1.39–5.05). All episodes involved skin and soft-tissue infections; 17% required hospitalization, 35% surgery, and 51% received non-active empirical antibiotics. Recurrent infections occurred in 32% of participants, and detectable HIV viral load was present in 28% of episodes. High levels of polydrug use were reported. Resistance to clindamycin (33%), cotrimoxazole (23%), and mupirocin (96%) was observed. Decolonization was attempted in 65% of participants. Conclusions: CA-MRSA infections were frequent, with substantial recurrence and antimicrobial resistance. These findings highlight challenges for infection control and antimicrobial stewardship and support further evaluation of preventive and decolonization strategies in this population.
- Open Access
- 11 June 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (8) , 2103-2119
Effectiveness, Sex Differences, and Patient Experience in Real-World Use of Long-Acting Cabotegravir and Rilpivirine: Results from a Prospective Study
Introduction Long-acting intramuscular cabotegravir plus rilpivirine (LA-CAB/RPV) administered every 2 months (Q2M) has been available in Spain since January 2023 as a switch strategy for HIV treatment. We evaluated characteristics, effectiveness, tolerability, and acceptance, including patient-reported outcomes, stratified by sex in people with HIV switching to LA-CAB/RPV. Methods Observational, prospective, cohort study in Hospital Clínic of Barcelona, Spain. Participant characteristics according to sex at birth and treatment effectiveness [HIV-RNA < 50 copies/mL by on treatment (OT), modified intention-to-treat (mITT), and intention to-treat (ITT) analyses] were evaluated. Self-administered electronic questionnaires were collected. Results From February 2023 to February 2025, 57/741 (8%) women and 684/741 (92%) men started LA-CAB/RPV, compared to 816/5901 (14%) women that continued with other antiretroviral therapy (ART) (p < 0.001) in our cohort. Women were older, had longer time since HIV diagnosis and on ART, lower nadir CD4, and were more frequently Spanish-born than men. Effectiveness by OT, mITT, and ITT in the 461 participants (29 women and 432 men) who reached week 52 of follow-up was 96%, 83%, and 83% and 99%, 92%, and 89%, respectively, without significant differences. There were 8 (1.7%) confirmed virological failures and 40 (9%) discontinuations with no significant differences by sex. Acceptance, tolerability of injections, and HIV medication burden globally improved during follow-up. Women reported more medication burden and disclosure worries than men. Conclusions Compared to our general cohort, proportionally fewer women than men switched to LA-CAB/RPV. Effectiveness, adherence, tolerability, and acceptance were high without significant differences by sex. In this study, women expressed more frequent disclosure issues and showed significantly different baseline characteristics compared to men, highlighting the importance of sex-disaggregated data analysis. These results should be confirmed in larger studies.
- 11 June 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (8) , 2103-2119
Open AccessEffectiveness, Sex Differences, and Patient Experience in Real-World Use of Long-Acting Cabotegravir and Rilpivirine: Results from a Prospective Study
Introduction Long-acting intramuscular cabotegravir plus rilpivirine (LA-CAB/RPV) administered every 2 months (Q2M) has been available in Spain since January 2023 as a switch strategy for HIV treatment. We evaluated characteristics, effectiveness, tolerability, and acceptance, including patient-reported outcomes, stratified by sex in people with HIV switching to LA-CAB/RPV. Methods Observational, prospective, cohort study in Hospital Clínic of Barcelona, Spain. Participant characteristics according to sex at birth and treatment effectiveness [HIV-RNA < 50 copies/mL by on treatment (OT), modified intention-to-treat (mITT), and intention to-treat (ITT) analyses] were evaluated. Self-administered electronic questionnaires were collected. Results From February 2023 to February 2025, 57/741 (8%) women and 684/741 (92%) men started LA-CAB/RPV, compared to 816/5901 (14%) women that continued with other antiretroviral therapy (ART) (p < 0.001) in our cohort. Women were older, had longer time since HIV diagnosis and on ART, lower nadir CD4, and were more frequently Spanish-born than men. Effectiveness by OT, mITT, and ITT in the 461 participants (29 women and 432 men) who reached week 52 of follow-up was 96%, 83%, and 83% and 99%, 92%, and 89%, respectively, without significant differences. There were 8 (1.7%) confirmed virological failures and 40 (9%) discontinuations with no significant differences by sex. Acceptance, tolerability of injections, and HIV medication burden globally improved during follow-up. Women reported more medication burden and disclosure worries than men. Conclusions Compared to our general cohort, proportionally fewer women than men switched to LA-CAB/RPV. Effectiveness, adherence, tolerability, and acceptance were high without significant differences by sex. In this study, women expressed more frequent disclosure issues and showed significantly different baseline characteristics compared to men, highlighting the importance of sex-disaggregated data analysis. These results should be confirmed in larger studies.
- Top Cited Papers
- 14 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , 1015-1022
Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles
Background: Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) therapy for HIV, lacks activity against hepatitis B virus (HBV). We evaluate HBV serological profiles and risk of HBV reactivation (HBVr) or incident infection (HBVi) in people with HIV (PWH) switching to LA-CAB/RPV. Methods: Prospective cohort study of PWH initiating LA-CAB/RPV at Hospital Clínic Barcelona between February/2023 and February/2025. HBV serology, vaccination status, and liver function tests (LFTs) were assessed at baseline. Follow-up LFTs were performed routinely (weeks 12, 28, and every 6 months), and HBV serology/DNA assessed if abnormal LFTs, acute hepatitis or clinical suspicion of reactivation. HBVr was defined as conversion from HBsAg negative to positive or detectable HBV DNA in anti-HBc-positive/HBsAg-negative individuals, or as HBV DNA ≥1 log increase or ≥100 IU/mL in chronic HBV (HBsAg-positive) participants. HBVi was defined as HBsAg seroconversion in HBV unexposed individuals. Results: Among 741 participants-92% cis-gender male, median age 43 (IQR 35–52)-454 (61%) had vaccine-induced immunity and 25% had prior HBV exposure (anti-HBc-positive), with 3% showing isolated anti-HBc. Median follow-up was 54 weeks (IQR 28–77). No HBVr or HBVi were observed in people without chronic hepatitis at baseline. Four individuals (0.5%) with unnoticed chronic HBV infection (HBsAg-positive) started LA-CAB/RPV; two developed clinical HBVr and two remained stable after regimen switch, all four switched back to tenofovir-containing therapy. Transaminase elevations during follow-up occurred in 17% of the cohort, regardless of HBV serostatus. Conclusions: LA-CAB/RPV appears safe in individuals with prior HBV exposure, including isolated anti-HBc. Comprehensive HBV screening, vaccination, and liver monitoring are essential.
- 14 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , 1015-1022
Top Cited PapersHepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles
Background: Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) therapy for HIV, lacks activity against hepatitis B virus (HBV). We evaluate HBV serological profiles and risk of HBV reactivation (HBVr) or incident infection (HBVi) in people with HIV (PWH) switching to LA-CAB/RPV. Methods: Prospective cohort study of PWH initiating LA-CAB/RPV at Hospital Clínic Barcelona between February/2023 and February/2025. HBV serology, vaccination status, and liver function tests (LFTs) were assessed at baseline. Follow-up LFTs were performed routinely (weeks 12, 28, and every 6 months), and HBV serology/DNA assessed if abnormal LFTs, acute hepatitis or clinical suspicion of reactivation. HBVr was defined as conversion from HBsAg negative to positive or detectable HBV DNA in anti-HBc-positive/HBsAg-negative individuals, or as HBV DNA ≥1 log increase or ≥100 IU/mL in chronic HBV (HBsAg-positive) participants. HBVi was defined as HBsAg seroconversion in HBV unexposed individuals. Results: Among 741 participants-92% cis-gender male, median age 43 (IQR 35–52)-454 (61%) had vaccine-induced immunity and 25% had prior HBV exposure (anti-HBc-positive), with 3% showing isolated anti-HBc. Median follow-up was 54 weeks (IQR 28–77). No HBVr or HBVi were observed in people without chronic hepatitis at baseline. Four individuals (0.5%) with unnoticed chronic HBV infection (HBsAg-positive) started LA-CAB/RPV; two developed clinical HBVr and two remained stable after regimen switch, all four switched back to tenofovir-containing therapy. Transaminase elevations during follow-up occurred in 17% of the cohort, regardless of HBV serostatus. Conclusions: LA-CAB/RPV appears safe in individuals with prior HBV exposure, including isolated anti-HBc. Comprehensive HBV screening, vaccination, and liver monitoring are essential.
- Open Access
Incidence, Clinical Features and Vaccination Coverage of Pneumococcal Disease in People Living with HIV: A Retrospective Cohort Study (2015–2024)
Introduction: The incidence of pneumococcal disease (PD) in people living with HIV (PLWH) is higher than in the general population; therefore, this study aimed to analyze its incidence, clinical characteristics and vaccination coverage in PLWH. Methods: We conducted a retrospective, single-center study between 2015 and 2024 in Hospital Clínic, Barcelona, involving HIV patients who presented with PD during the study period (any patient with a microbiologically confirmed result). A descriptive analysis of cases was carried out and compared with patients who did not present PD during the study period. Results: A total of 177 episodes of PD were identified in 148 individuals, with a cumulative incidence of 1.7% (95% CI: 1.4–2.0). The median age at PD diagnosis was 45.9 (36–53) years; 64% of patients were Spanish-born; 50% of patients were men who have sex with men (MSM); the HIV transmission mode was intravenous drug use in 28% of cases; the median CD4 nadir was 181 (58–324) cells/mm3; the median CD4 prior to PD was 429 (240–663) cells/mm3; and the median peak HIV viral load (VL) was 176,839 (20,900–502,000) copies/mL. Intravenous drug use (OR 3.43; 95% CI 2.19–5.36; p < 0.001), peak HIV VL (OR 1.11; 95% CI 1.02–1.21; p = 0.011), and CD4 nadir (OR 0.92; 95% CI 0.87–0.98; p = 0.005) were independently associated with PD, and fifty-one percent of patients had not received any vaccination prior to their PD episode. Conclusion: PD incidence was high in our study and associated with poor immunological status. Research on new strategies to improve vaccination coverage and immunogenicity in PLWH is needed.
Open AccessIncidence, Clinical Features and Vaccination Coverage of Pneumococcal Disease in People Living with HIV: A Retrospective Cohort Study (2015–2024)
Introduction: The incidence of pneumococcal disease (PD) in people living with HIV (PLWH) is higher than in the general population; therefore, this study aimed to analyze its incidence, clinical characteristics and vaccination coverage in PLWH. Methods: We conducted a retrospective, single-center study between 2015 and 2024 in Hospital Clínic, Barcelona, involving HIV patients who presented with PD during the study period (any patient with a microbiologically confirmed result). A descriptive analysis of cases was carried out and compared with patients who did not present PD during the study period. Results: A total of 177 episodes of PD were identified in 148 individuals, with a cumulative incidence of 1.7% (95% CI: 1.4–2.0). The median age at PD diagnosis was 45.9 (36–53) years; 64% of patients were Spanish-born; 50% of patients were men who have sex with men (MSM); the HIV transmission mode was intravenous drug use in 28% of cases; the median CD4 nadir was 181 (58–324) cells/mm3; the median CD4 prior to PD was 429 (240–663) cells/mm3; and the median peak HIV viral load (VL) was 176,839 (20,900–502,000) copies/mL. Intravenous drug use (OR 3.43; 95% CI 2.19–5.36; p < 0.001), peak HIV VL (OR 1.11; 95% CI 1.02–1.21; p = 0.011), and CD4 nadir (OR 0.92; 95% CI 0.87–0.98; p = 0.005) were independently associated with PD, and fifty-one percent of patients had not received any vaccination prior to their PD episode. Conclusion: PD incidence was high in our study and associated with poor immunological status. Research on new strategies to improve vaccination coverage and immunogenicity in PLWH is needed.